Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 17 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Astec Lifesciences Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 15, 2024, 4:01 pm

Market Cap 2,077 Cr.
Current Price 1,059
High / Low1,488/825
Stock P/E
Book Value 149
Dividend Yield0.00 %
ROCE4.48 %
ROE11.9 %
Face Value 10.0
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Astec Lifesciences Ltd

Competitors of Astec Lifesciences Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Epigral Ltd 8,876 Cr. 2,0572,408/88630.3 3370.24 %17.5 %16.9 % 10.0
Dharmaj Crop Guard Ltd 974 Cr. 288390/19724.1 1170.00 %14.5 %13.2 % 10.0
Bhaskar Agrochemicals Ltd 34.2 Cr. 65.6122/44.217.3 29.20.00 %14.7 %13.4 % 10.0
Bhagiradha Chemicals & Industries Ltd 4,086 Cr. 328448/117152 51.00.03 %9.69 %6.27 % 1.00
Best Agrolife Ltd 1,434 Cr. 606918/45438.9 3200.49 %16.5 %18.1 % 10.0
Industry Average12,020.16 Cr1,745.1742.12387.580.31%13.80%15.51%7.35

All Competitor Stocks of Astec Lifesciences Ltd

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales11617212910317327218420011712714311151
Expenses1001341048113020715916610512214011469
Operating Profit16382521436525331253-3-18
OPM %13%22%19%21%25%24%14%17%10%4%2%-3%-36%
Other Income3211273443211
Interest1122334566666
Depreciation77789119898999
Profit before tax11321712335815251-6-11-18-32
Tax %37%26%26%26%25%26%25%25%31%20%26%24%24%
Net Profit724139254311181-5-8-13-24
EPS in Rs3.6112.236.634.6312.6321.975.829.340.43-2.54-4.18-6.85-12.41

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales112174207267233299368431523555677628431
Expenses97146171213201236299354437443522551445
Operating Profit16283554326369768511215477-13
OPM %14%16%17%20%14%21%19%18%16%20%23%12%-3%
Other Income10-0-164-8121112810136
Interest679131312111213592125
Depreciation9121513101415192326343435
Profit before tax29111312295656618912135-67
Tax %29%32%22%-17%59%33%37%36%23%27%26%27%
Net Profit16915519353648659026-51
EPS in Rs0.813.304.687.602.559.8017.8718.2824.2833.2145.8513.04-25.98
Dividend Payout %62%23%21%16%0%15%8%8%6%5%3%12%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)500.00%50.00%66.67%-66.67%280.00%84.21%2.86%33.33%35.42%38.46%-71.11%
Change in YoY Net Profit Growth (%)0.00%-450.00%16.67%-133.33%346.67%-195.79%-81.35%30.48%2.08%3.04%-109.57%

Astec Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:8%
5 Years:1%
3 Years:-6%
TTM:-25%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:-302%
Stock Price CAGR
10 Years:26%
5 Years:24%
3 Years:-8%
1 Year:-16%
Return on Equity
10 Years:13%
5 Years:11%
3 Years:6%
Last Year:-12%

Last Updated: Unknown

Balance Sheet

Last Updated: November 15, 2024, 1:40 am

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital18191919202020202020202020
Reserves879511699119150183227290377400350272
Borrowings73839312712712517699187279341494500
Other Liabilities838813385691198322618122121911290
Total Liabilities261284362330334413461572678897979975882
Fixed Assets12113213395103115167194213340318386539
CWIP13612208421924116231271652
Investments0000000000000
Other Assets127146216215223256275354349534534424341
Total Assets261284362330334413461572678897979975882

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +16157-13196515168-8247510
Cash from Investing Activity +-13-19-19-17-18-49-52-74-73-104-113-135
Cash from Financing Activity +-231231-1-1837-95818038125
Net Cash Flow1-1-021-3-0000-00

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow16.00-45.00-48.00-39.00-95.00-64.00-56.00-100.00-14.00-75.00-125.00-264.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days1319114212613512210311212314890135
Inventory Days145192147177133122121131113176268224
Days Payable13211417916911615583218137179161102
Cash Conversion Cycle1451681091341528914225100145197256
Working Capital Days12212512514215411514777101163175234
ROCE %9%11%20%12%20%22%20%20%22%22%8%-4%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters65.20%65.19%65.29%65.29%66.77%66.76%66.76%66.76%66.75%66.75%66.75%66.75%
FIIs0.22%0.29%0.32%0.48%1.53%2.19%2.29%1.95%1.33%1.28%1.25%1.03%
DIIs12.21%12.74%12.56%11.79%9.82%9.57%10.58%10.15%10.16%9.74%7.88%3.37%
Public22.37%21.78%21.83%22.45%21.87%21.49%20.37%21.13%21.74%22.22%24.12%28.85%
No. of Shareholders21,07319,00216,95117,43317,63219,54517,80918,70318,72219,24419,84819,955

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Nippon India Small Cap Fund468,5890.1762.02468,5892024-11-140%
ICICI Prudential Multicap Fund457,6690.6960.58468,5892024-11-14-2.33%
ICICI Prudential Smallcap Fund452,5460.9959.9468,5892024-11-14-3.42%
Nippon India Multi Cap Fund257,7180.1634.11468,5892024-11-14-45%
ICICI Prudential Commodities Fund112,3601.1214.87468,5892024-11-14-76.02%
ICICI Prudential MidCap Fund15,8440.052.1468,5892024-11-14-96.62%
ITI Value Fund11,9231.131.58468,5892024-11-14-97.46%
ITI Pharma and Healthcare Fund11,7541.151.56468,5892024-11-14-97.49%
Motilal Oswal Nifty Microcap 250 Index Fund5,3710.180.71468,5892024-11-14-98.85%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)-23.9313.0445.8733.2324.29
Diluted EPS (Rs.)-23.9313.0445.8533.2124.27
Cash EPS (Rs.)-5.4230.2263.3946.3236.13
Book Value[Excl.RevalReserv]/Share (Rs.)188.44214.00202.40157.91126.17
Book Value[Incl.RevalReserv]/Share (Rs.)188.44214.00202.40157.91126.17
Revenue From Operations / Share (Rs.)233.66320.40345.23283.28267.07
PBDIT / Share (Rs.)-0.1345.5683.9661.0049.63
PBIT / Share (Rs.)-18.6228.3966.4347.9037.79
PBT / Share (Rs.)-31.4917.8261.8145.4731.35
Net Profit / Share (Rs.)-23.9113.0545.8633.2224.29
NP After MI And SOA / Share (Rs.)-23.9313.0445.8533.2124.28
PBDIT Margin (%)-0.0514.2124.3121.5318.58
PBIT Margin (%)-7.978.8619.2416.9014.14
PBT Margin (%)-13.475.5617.9016.0511.73
Net Profit Margin (%)-10.234.0713.2811.729.09
NP After MI And SOA Margin (%)-10.244.0613.2811.729.09
Return on Networth / Equity (%)-12.706.0922.6621.0319.26
Return on Capital Employeed (%)-6.3212.2832.0526.4029.18
Return On Assets (%)-4.812.6110.029.608.31
Long Term Debt / Equity (X)0.530.020.000.120.00
Total Debt / Equity (X)1.340.810.700.600.40
Asset Turnover Ratio (%)0.460.660.850.881.01
Current Ratio (X)1.000.941.051.031.04
Quick Ratio (X)0.510.380.670.690.66
Inventory Turnover Ratio (X)1.301.913.043.033.12
Dividend Payout Ratio (NP) (%)-6.2611.503.264.516.17
Dividend Payout Ratio (CP) (%)-27.544.962.363.234.15
Earning Retention Ratio (%)106.2688.5096.7495.4993.83
Cash Earning Retention Ratio (%)127.5495.0497.6496.7795.85
Interest Coverage Ratio (X)-0.014.3118.1725.157.71
Interest Coverage Ratio (Post Tax) (X)-0.852.2410.9214.694.77
Enterprise Value (Cr.)2574.293049.603711.792144.94880.19
EV / Net Operating Revenue (X)5.624.855.493.871.68
EV / EBITDA (X)-9580.5334.1422.5617.959.06
MarketCap / Net Operating Revenue (X)4.554.315.083.531.50
Retention Ratios (%)106.2688.4996.7395.4893.82
Price / BV (X)5.646.468.666.343.17
Price / Net Operating Revenue (X)4.554.315.083.531.50
EarningsYield-0.020.010.020.030.06

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Astec Lifesciences Ltd as of November 17, 2024 is: 271.28

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 17, 2024, Astec Lifesciences Ltd is Overvalued by 74.38% compared to the current share price 1,059.00

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of Astec Lifesciences Ltd as of November 17, 2024 is: 123.44

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 17, 2024, Astec Lifesciences Ltd is Overvalued by 88.34% compared to the current share price 1,059.00

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -54.50%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 15.17%, which is a positive sign.
  2. The company has higher reserves (212.69 cr) compared to borrowings (208.00 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (377.31 cr) and profit (32.85 cr) over the years.
  1. The stock has a high average Working Capital Days of 140.00, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 138.50, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Astec Lifesciences Ltd:
    1. Net Profit Margin: -10.23%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: -6.32% (Industry Average ROCE: 13.8%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: -12.7% (Industry Average ROE: 15.51%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): -0.85
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.51
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 0 (Industry average Stock P/E: 42.12)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 1.34
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Astec Lifesciences Ltd. is a Public Limited Listed company incorporated on 25/01/1994 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L99999MH1994PLC076236 and registration number is 076236. Currently Company is involved in the business activities of Manufacture of insecticides, rodenticides, fungicides, herbicides. Company’s Total Operating Revenue is Rs. 676.57 Cr. and Equity Capital is Rs. 19.60 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Agro Chemicals/PesticidesGodrej One, 3rd Floor, Pirojshanagar, Mumbai Maharashtra 400079astecinfo@godrejastec.com
www.godrejastec.com
Management
NamePosition Held
Mr. Nadir B GodrejChairman
Mr. Ashok V HiremathNon Executive Director
Mr. Balram Singh YadavNon Executive Director
Mr. Anurag RoyDirector
Dr. Brahma Nand VyasIndependent Director
Mr. R R GovindanIndependent Director
Mr. Nandkumar DhekneIndependent Director
Ms. Anjali GupteIndependent Director
Mr. Burjis Nadir GodrejNon Executive Director

FAQ

What is the latest intrinsic value of Astec Lifesciences Ltd?

The latest intrinsic value of Astec Lifesciences Ltd as on 17 November 2024 is ₹271.28, which is 74.38% lower than the current market price of ₹1,059.00.

What is the Market Cap of Astec Lifesciences Ltd?

The Market Cap of Astec Lifesciences Ltd is 2,077 Cr..

What is the current Stock Price of Astec Lifesciences Ltd as on 17 November 2024?

The current stock price of Astec Lifesciences Ltd as on 17 November 2024 is ₹1,059.

What is the High / Low of Astec Lifesciences Ltd stocks in FY 2024?

In FY 2024, the High / Low of Astec Lifesciences Ltd stocks is 1,488/825.

What is the Stock P/E of Astec Lifesciences Ltd?

The Stock P/E of Astec Lifesciences Ltd is .

What is the Book Value of Astec Lifesciences Ltd?

The Book Value of Astec Lifesciences Ltd is 149.

What is the Dividend Yield of Astec Lifesciences Ltd?

The Dividend Yield of Astec Lifesciences Ltd is 0.00 %.

What is the ROCE of Astec Lifesciences Ltd?

The ROCE of Astec Lifesciences Ltd is 4.48 %.

What is the ROE of Astec Lifesciences Ltd?

The ROE of Astec Lifesciences Ltd is 11.9 %.

What is the Face Value of Astec Lifesciences Ltd?

The Face Value of Astec Lifesciences Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Astec Lifesciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE